Non-Human Primates Critical to Development of New Migraine Medication

The Hill reported on May 17 that the Food and Drug Administration (FDA) has approved a new medication to prevent migraine headaches. The new drug is called erenumab-aooe, trademarked as Aimovig, and is produced by Amgen and Novartis. In trials, Aimovig helped patients experience at least a 50 percent reduction in the total number of days in which they suffered a migraine.

Nonhuman primate (NHP) research was critical to testing the drug’s safety for pregnant woman and their unborn children. The FDA states, “No adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation. Serum erenumab-aooe exposures in pregnant monkeys were greater than those in humans at clinical doses.”

Nonhuman primates have been, and will continue to be, critical to medical research. The Foundation for Biomedical Research (FBR) provides an excellent white paper and brochure on this topic, and we encourage you to read both.